US Stock MarketDetailed Quotes

GUTS Fractyl Health

Watchlist

2.320
+0.015+0.65%

Close Oct 2 16:00 ET

111.19MMarket Cap-1687P/E (TTM)

Fractyl Health Stock Forum

Stock_Drift

Yesterday 06:14

After hours Ticks, 5:12pm EST.

$S&W Seed (SANW.US)$ $Fractyl Health (GUTS.US)$ $Volcon (VLCN.US)$ $Eterna Therapeutics (ERNA.US)$ $Lazydays (GORV.US)$ $Adagio Medical (ADGM.US)$ $EXCELFIN ACQUISITION CORP (XFIN.US)$ $Treasure Global (TGL.US)$ $HWH International (HWH.US)$ $iCoreConnect (ICCT.US)$
📊⚡️📊

Trytosaveabit

Aug 8 07:29

Update

$Fractyl Health (GUTS.US)$ Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure
Globe Newswire 8-Aug-2024

Trytosaveabit

Jul 30 06:04

Update

$Fractyl Health (GUTS.US)$ Reuters· 3 mins ago
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People With Obesity Who Discontinue GLP-1 Based Drugs

FattyChick

Jul 30 06:01

$Fractyl Health (GUTS.US)$ Too many obesity drugs nowadays…

Trytosaveabit

May 20 05:49

Update

$Fractyl Health (GUTS.US)$ Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024. VIA GLOBENEWSWIRE Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42%

Trytosaveabit

May 13 17:14

Looks way more impressive than it is! Hehehe. But who knows, it is a great increase.

$Fractyl Health (GUTS.US)$ Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.

Stock Region

Apr 2 06:50

Health Company Receives FDA Approval For Obesity Drug Study

A Revolutionary Step in Obesity Management: The Approval of Fractyl Health's Revita® Remain-1 Study.
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...

Trytosaveabit

Apr 1 06:45

How s*itty of a trick! Hehehe

$Fractyl Health (GUTS.US)$ No longer looking for reversal! They release FDA news to get the PI! Then they release the big ole earnings loss! Hehehe!

Trytosaveabit

Apr 1 05:17

Looking for reversal

$Fractyl Health (GUTS.US)$ Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Globe Newswire 1-Apr-2024 6:00 AM

Ant-waan

Mar 20 03:25

$BitFuFu (FUFU.US)$ Good morning Traders in the world Good Luck to you all 👋 $BitFuFu (FUFU.US)$ $Haoxi Health Technology (HAO.US)$ $Jin Medical International (ZJYL.US)$ $Lavoro (LVRO.US)$ $Golden Sun Health Technology (GSUN.US)$ $Fractyl Health (GUTS.US)$ $Etao International (ETAO.US)$ $Oblong (OBLG.US)$ $Mangoceuticals (MGRX.US)$

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data